{"id":140665,"date":"2026-08-05T09:23:13","date_gmt":"2026-08-05T09:23:13","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/140665\/"},"modified":"2026-08-05T09:23:13","modified_gmt":"2026-08-05T09:23:13","slug":"novo-ceo-faces-investor-grilling-after-obesity-drug-disappointments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/140665\/","title":{"rendered":"Novo CEO faces investor grilling after obesity drug disappointments"},"content":{"rendered":"<p>            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/08\/gettyimages-1739574189.jpeg\" alt=\"Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one country after the other. \" height=\"720\" width=\"1080\" loading=\"lazy\"\/><\/p>\n<p>\n                    Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one country after the other.\n                <\/p>\n<p>\n            Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.\n        <\/p>\n","protected":false},"excerpt":{"rendered":"Ozempic manufacturer Novo Nordisk faces challenges as the patent on semaglutide expire in one country after the other.&hellip;\n","protected":false},"author":2,"featured_media":140666,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[34557,272,3102,358,1910,277],"class_list":["post-140665","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-know","tag-novo-nordisk","tag-ozempic","tag-pharmaceuticals","tag-wegovy","tag-weight-loss-drugs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117042178067414934","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/140665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=140665"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/140665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/140666"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=140665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=140665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=140665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}